Navigation Links
AlphaRx's Indaflex(TM) Continues its Clinical Development
Date:5/12/2008

MARKHAM, ON, May 12 /PRNewswire-FirstCall/ - AlphaRx (OTC BB:ALRX - News), an emerging biopharmaceutical company utilizing proprietary drug delivery technology to develop novel formulations of drugs, is pleased to announce that the clinical development of Indaflex(TM), its topical NSAID (Non-Steroidal Anti-Inflammatory Drug) formulation, will continue as part of Cypress Bioscience, Inc. ("Cypress') (NASDAQ: CYPB).

In March 2008, Cypress acquired Proprius Pharmaceuticals, Inc. ("Proprius"). The transaction included an upfront payment of approximately $37.5 million in cash, as well as an additional $37.5 million in potential milestone-related payments associated with the development of Proprius' therapeutic candidates including Indaflex(TM). AlphaRx was notified that the Indaflex licensing agreement has been assigned to Cypress from Proprius as part of that transaction.

Michael Lee, President of AlphaRx stated, "AlphaRx is excited to see the development of Indaflex continue as part of Cypress' on-going clinical development efforts. We believe Indaflex is in good hands and is consistent with Cypress's therapeutic focus and expertise."

About AlphaRx Inc.

AlphaRx is a specialty pharmaceutical company utilizing proprietary site-specific nanoparticulate drug delivery systems to develop novel formulations of drugs that are insoluble or poorly soluble in water or have yet to be administrable to the human body with an acceptable delivery method. The Company's product candidates address various pharmaceutical markets, including inflammation, tuberculosis and pneumonia.

Forward Looking Statements:

This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the companies.

Copyright @ 2008. AlphaRx Inc.


'/>"/>
SOURCE AlphaRx Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Battle Continues Over Vietnam PTSD Numbers
2. U.S. Research Funding Continues to Flatten as U.S. Health Costs Climb - in August 31 Science
3. Therap Services Continues to Hire Experienced Developmental Disability Industry Clinicians for its Customer Support Team
4. Securians Minnesota Life Continues to Climb Group Life Rankings
5. USA TODAY Continues Spirit of the USA Charity Program as Part of Newspapers 25th Anniversary Celebration
6. United States continues to have highest level of health spending
7. LehmanMillet Continues Expansion with Strategic Hires
8. American Cancer Society report finds breast cancer death rate continues to drop
9. CIGNA HealthCare Continues Gains in Health Care Quality
10. Los Angeles Jewish Home Support Group Continues High-Profile Speaker Program With Noted Legal Scholar and Expert Laurie L. Levenson
11. Volkswagen Continues Sponsorship of the Lasalle Bank Chicago Marathon
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... VA (PRWEB) , ... May 24, 2016 , ... Controlling ... smarter - with the launch of the Aquanta Water Heater Controller , a ... smart phone or web-enabled device. As the Nest thermostat does for HVAC systems, ...
(Date:5/24/2016)... WI (PRWEB) , ... May 24, 2016 , ... ... In Milwaukee , Out patient Services To Begin In June , Aloria Health, ... pleased to announce the opening of Aloria Milwaukee, its first treatment facility for ...
(Date:5/24/2016)... NJ (PRWEB) , ... May 24, 2016 , ... The ... that’s causing the problem. A common injury that’s often misunderstood, whiplash should be swiftly ... MD, a Harvard-trained, orthopedic spine surgeon at Atlantic Spine Center . , ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... successful implementation of protocols designed to reduce bleeding complications from percutaneous coronary intervention ... Angiography and Interventions (SCAI) in Orlando, FL, document a 40% reduction in risk-adjusted ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... Essette Dashboard, its highly anticipated, web-based software module. The cutting-edge feature provides ... “secret sauce”? Integration with Izenda’s self-service business intelligence solution and its analytics ...
Breaking Medicine News(10 mins):
(Date:5/19/2016)... According to a new market research report "Sunitinib Malate ... Germany , France , U.K., ... Japan )", published by MarketsandMarkets, The market is projected to ... from 2016 to 2021.      (Logo: http://photos.prnewswire.com/prnh/20160303/792302 ... through 26 Pages and in-depth TOC on "Sunitinib Malate ...
(Date:5/19/2016)... AVIV, Israel , May 19, 2016 ... or the "Company"), an emerging global ophthalmic company focused ... product candidates which address ophthalmic conditions, announced today that ... Italy ) for the manufacturing, distribution, ... product for the treatment of dry eye syndrome (DES) ...
(Date:5/19/2016)... May 19, 2016 At the 18 ... Meeting in Amsterdam , (May 15-19), Elekta ... clinically-proven radiosurgery system available, has been used in the ... brain tumors, vascular malformations and functional disorders. ... 75,000 patients every year in hundreds of leading hospitals ...
Breaking Medicine Technology: